📊 CADL Key Takeaways
Is Candel Therapeutics, Inc. (CADL) a Good Investment?
Candel Therapeutics is a pre-revenue biotech company with minimal commercial traction ($102K revenue) and significant operating losses (-$16.3M). While the balance sheet is resilient with $194.8M cash and low debt, the company is burning ~$18.7M annually with no pathway to profitability demonstrated in current fundamentals. Without revenue growth or cost discipline, the company's viability depends entirely on future product success not yet reflected in SEC data.
Candel Therapeutics shows very weak operating fundamentals, with essentially no revenue base against large and recurring losses, deeply negative margins, and substantial cash burn. The balance sheet is supported by a large cash position and strong near-term liquidity, but growth quality is poor and the business remains dependent on external capital or future clinical/commercial milestones to improve sustainability.
Candel Therapeutics, Inc. Key Strengths (CADL)
- Strong liquidity position with $194.8M cash providing 10+ year runway at current burn rate
- Conservative capital structure with 0.34x debt-to-equity ratio and manageable $46.4M long-term debt
- Adequate near-term financial cushion to execute clinical development without immediate dilution pressure
- Very strong short-term liquidity with $119.73M in cash and a 13.49x current ratio
- Moderate balance sheet support from $51.92M in equity relative to total assets of $125.19M
- Net loss per share improved year over year, indicating some reduction in per-share loss pressure
CADL Stock Risks: Candel Therapeutics, Inc. Investment Risks
- Pre-revenue stage with only $102K in revenue indicates no meaningful commercial traction or product adoption
- Significant operating cash burn of $18.0M annually with negative free cash flow of -$18.7M constrains operational flexibility
- Massive negative margins (-15,965% operating margin) and lack of path to profitability visible in current financials suggest high execution risk
- Revenue remains negligible at $102.00K, showing no meaningful commercial scale or operating traction
- Heavy operating and free cash flow losses suggest the business is not self-funding and may require future financing
- Leverage is meaningful for a loss-making company, with $46.12M in long-term debt and negative interest coverage
Key Metrics to Watch
- Operating cash burn rate and runway remaining before funding necessity
- Revenue growth trajectory and commercialization milestones
- Operating margin improvement and timeline to cash flow breakeven
- Quarterly operating cash burn and cash runway
- Revenue growth and progress toward narrowing operating losses
Candel Therapeutics, Inc. (CADL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 28.05x current ratio provides a solid financial cushion.
CADL Profit Margin, ROE & Profitability Analysis
CADL vs Healthcare Sector: How Candel Therapeutics, Inc. Compares
How Candel Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Candel Therapeutics, Inc. Stock Overvalued? CADL Valuation Analysis 2026
Based on fundamental analysis, Candel Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Candel Therapeutics, Inc. Balance Sheet: CADL Debt, Cash & Liquidity
CADL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Candel Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.74 indicates the company is currently unprofitable.
CADL Revenue Growth, EPS Growth & YoY Performance
CADL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $31.0K | -$8.4M | $-0.29 |
| Q2 2023 | $31.0K | -$4.1M | $-0.14 |
| Q1 2023 | $31.0K | -$874.0K | $-0.03 |
| Q3 2022 | $31.0K | -$8.7M | $-0.30 |
| Q2 2022 | $31.0K | -$4.1M | $-0.14 |
| Q1 2022 | $31.0K | -$874.0K | N/A |
| Q3 2021 | $31.0K | -$2.6M | N/A |
| Q2 2021 | $31.0K | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Candel Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CADL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Candel Therapeutics, Inc. (CIK: 0001841387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CADL
What is the AI rating for CADL?
Candel Therapeutics, Inc. (CADL) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CADL's key strengths?
Claude: Strong liquidity position with $194.8M cash providing 10+ year runway at current burn rate. Conservative capital structure with 0.34x debt-to-equity ratio and manageable $46.4M long-term debt. ChatGPT: Very strong short-term liquidity with $119.73M in cash and a 13.49x current ratio. Moderate balance sheet support from $51.92M in equity relative to total assets of $125.19M.
What are the risks of investing in CADL?
Claude: Pre-revenue stage with only $102K in revenue indicates no meaningful commercial traction or product adoption. Significant operating cash burn of $18.0M annually with negative free cash flow of -$18.7M constrains operational flexibility. ChatGPT: Revenue remains negligible at $102.00K, showing no meaningful commercial scale or operating traction. Heavy operating and free cash flow losses suggest the business is not self-funding and may require future financing.
What is CADL's revenue and growth?
Candel Therapeutics, Inc. reported revenue of $102.0K.
Does CADL pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
Where can I find CADL SEC filings?
Official SEC filings for Candel Therapeutics, Inc. (CIK: 0001841387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CADL's EPS?
Candel Therapeutics, Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CADL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Candel Therapeutics, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CADL stock overvalued or undervalued?
Valuation metrics for CADL: ROE of -6.4% (sector avg: 15%), net margin of -8,687.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CADL's AI grade for 2026?
Our dual AI analysis gives Candel Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CADL's free cash flow?
Candel Therapeutics, Inc.'s operating cash flow is $-18.0M, with capital expenditures of $675.0K. FCF margin is -18,345.1%.
How does CADL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8,687.3% (avg: 12%), ROE -6.4% (avg: 15%), current ratio 28.05 (avg: 2).